Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 3, Issue 73, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3002137
Keywords
-
Categories
Funding
- NIH [1DP1OD006432-01, 1R21HL092814-01]
- Center for Cancer Nanotechnology Excellence (NIH) [5-U54-CA119373-02]
Ask authors/readers for more resources
When treating metastatic tumors, chemoresistance can cause problems. A report in this issue of Science Translational Medicine demonstrates the potential of nanodiamond carriers (2 to 8 nanometers) for treating cancers with drug-efflux-based chemoresistance. Nanodiamond-mediated delivery of the chemotherapeutic doxorubicin (Dox) allowed for prolonged activity and increased apoptosis with decreased toxicity when compared with free Dox in liver cancer cells in culture as well as in vivo in mouse liver tumors. This finding may represent a broadly applicable strategy for overcoming adenosine 5'-triphosphate (ATP)-binding cassette (ABC) drug transporter-mediated resistance during cancer chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available